Medical Management of Type 2 Diabetes, (CHES) 8th Ed.
This course is only for CHES professionals.
New edition! As Type 2 diabetes continues to rise in prevalence around the world, it is important for clinicians to stay current and choose the most effective interventions. This edition covers oral medications, diet and lifestyle modifications, insulin regimens, and the latest clinical guidelines from ADA. Authors describe the progressive nature of Type 2 as they examine cardiovascular, microvascular, and neurologic complications; and illustrate behavior change methods.
This new 8th edition features:
- Evidence-based treatments and newest agents
- Expanded pharmacological interventions
- Updated data on treating complications
- New clinical guidelines
Choose between two options:
15-hours Program I.D. #SS114228_T2D152021 CHES 15 hours max / MCHES 8 hours
26-hours Program I.D. #SS114228_T2D26 CHES 26 Hours max/ MCHES 14 hours
Suggested Performance Indicators: 1.1.4, 1.2.2, 2.1.8, 4.1.1, 4.1.2, 4.2.7, 6.1.2, 6.1.8, 6.2.3, 6.3.8, 8.1.1, 8.1.2, 8.1.5, 8.3.1, 8.3.5, 8.3.7, 10.1.3, 10.2.9
740 Online/Web-based Course
1.1.1 Define priority populations to be assessed
1.2.3 Review related literature
1.4.2 Identify and analyze factors that impact health
1.3.1 Identify data collection instruments
2.3.3 Apply principles of evidence-based practice in selecting and or designing strategies and interventions
3.2.1 Develop training objectives
3.2.3 Identify needs of individuals involved in implementation
4.3.1 Identify existing data collection instruments
Upon successful completion, the users will be able to:
1. List the serum blood sugar and A1C levels used to diagnose diabetes in patients.
2. Identify two tests that may be used to diagnose gestational diabetes.
3. Describe four contributing factors besides obesity where Type 2 diabetes (T2DM) may happen.
4. Discuss metabolic syndrome or Type 2 diabetes incidence in minority populations and two contributing factors.
5. Identify four diagnostic criteria for metabolic syndrome.
6. Describe how insulin resistance can occur.
7. Explain one beneficial effect of GLP-1 RA.
8. Discuss the result of three studies where participants tried to aggressively reduce A1C to <6.0%.
9. Compare the weight loss benefits to T2DM patients of a low-carbohydrate versus low-fat eating pattern.
10. Identify the vitamin that must be checked and supplemented in T2DM patients taking Metformin.
11. Discuss three benefits of regular physical activity in patients with T2DM.
12. Identify three precautions for a person with T2DM beginning a new exercise program.
13. Name the initial drug of choice for newly diagnosed T2DM patients.
14. Identify the drug that is most effective in controlling blood sugar levels after insulin.
15. Compare and contrast two pros and cons of the following: Degludec, Glarine, NPH, Detemir, and fixed-ratio insulin/GLP-1 RA.
16. Discuss two reasons why a woman with T2DM should try to have an A1C <5.0% before conception.
17. Identify the goal for “time in range” for patients with T2DM using continuous glucose monitoring and explain why this is so important.
18. Explain why pregnant women with blood sugars over 200 mg/dL need to check their ketones.
19. Discuss why high-risk youth for T2DM should be checked for pancreatic autobodies.
20. Describe three symptoms of hypoglycemia and two corrections that patients can use to correct it.
21. Describe why an appropriate A1C goal for an elderly patient with dementia and co-morbidities could be higher.
22. Calculate the protein needs of otherwise healthy, active people with T2DM and a person with T2DM with chronic kidney disease not requiring dialysis.
23. Identify two dietary therapies for gastroparesis.
Why we chose this book
The editor and 18 contributing authors are well respected and experienced clinicians in diabetes care. The American Diabetes Association’s books and resources are known for their high-quality, evidence-based content.
About the author
Luigi Meneghini, MD, MBA, is Professor of Internal Medicine at the University of Texas Southwestern Medical Center, Division of Endocrinology, in Dallas, TX and Executive Director of the Parkland Health and Hospital System Global Diabetes Program. Prior to joining UT Southwestern, he was Professor of Clinical Medicine at the University of Miami Miller School of Medicine and Director of the Kosow Diabetes Treatment Center.